Browsed by
Tag: SENS

The Vindication of Dr. Aubrey de Grey and the Dangers of “Strategic Conservatism” in the Aging-Research Community – Article by Gennady Stolyarov II

The Vindication of Dr. Aubrey de Grey and the Dangers of “Strategic Conservatism” in the Aging-Research Community – Article by Gennady Stolyarov II

Gennady Stolyarov II

It appears that the Board of Directors of the SENS Research Foundation saw fit to release an Executive Summary of a second Investigative Report that was undertaken after that Board had summarily terminated Dr. Aubrey de Grey without due process. Those who followed this matter know that I did not think highly of the first “Investigative Report”. The second report is still methodologically flawed, in my view, but that is not the point, and so I will not fixate on that. The point is the conclusion, which is what I and many others anticipated: “In the end, after extensive review – and except as otherwise identified by the Firm in this Executive Summary in paragraphs one through seven, as well as in the separate Executive Summary dated September 10, 2021 concerning the Initial Investigation – we do not find evidence Dr. de Grey engaged in conduct that constituted unwelcome sexual conduct towards current or former SRF employees, or any person associated with SRF, since the founding of SRF.”

So, other than the initial allegations against Aubrey de Grey, which, at worst, would have consisted of him sending two questionable e-mails (which were overlooked by the recipient for nearly a decade) and making a joke in poor taste (which there is no evidence that he made), there is… no evidence… of any unwelcome conduct! So this was all… much ado about nothing! It was all… a tempest in a teapot, stirred up to displace Dr. de Grey from his position on the eve of his success in raising an unprecedented $28 million for true rejuvenation biotechnology research. As many have suggested, and as I will reiterate, any harassment allegations here were just a pretext. The real motive is the power struggle within the field, between the initial visionaries like Dr. de Grey who built it up from ideas alone to a vibrant network of organizations, and those who came later, riding on the visionaries’ coattails, and who mistakenly wish to “mainstream” the field by appealing to the gatekeeper institutions through rhetoric of “strategic conservatism” (one of Celine Halioua’s favorite terms – indeed, the underpinning of her goal to turn aging research into a “boring” field that gets rid of the radical-life-extension aspirations). The “strategic conservatives” cannot have a man with a long beard, who speaks of 1,000-year lifespans, as the spokesperson for this movement, so they needed to find a pretext to oust him. Not only that, but they managed to hoodwink those of more left-leaning sympathies by exploiting the tendency to automatically believe women who accuse influential men of harassment – even though believing such allegations here plays right into the hands of the same interests who would wish to corporatize and render exclusive the pursuit of longevity research, to “tone it down” so that gatekeeper institutions provide their grants and imprimatur of “respectability” while the general public gets no say and no benefit. Those on the Left who wish to support harassment victims have understandable motivations, but it is so, so easy to twist those motivations to the service of one of the very corporate networks whom those same left-leaning individuals profess to despise, often quite explicitly.

What the “strategic conservatives” did not realize is that the grassroots movement that has emerged over the years to support the vision of SENS and the pursuit of longevity escape velocity is simply not inspired by the timid focus on “healthspan” or “compression of morbidity”. By getting rid of the ambitious visionaries who lit the spark of this movement, the “strategic conservatives” also undermine the foundation beneath themselves. They will not succeed in “mainstreaming” anything, because the gatekeeper institutions and their spokespeople see right through any version of the toned-down rhetoric anyway. What they may succeed at, unfortunately, is in ruining the crucial philanthropic sector within longevity / rejuvenation research, which will be needed for a long time to bridge the gap between early-stage academic research and late-stage commercial application. We need for-profit corporations and investors in the field as well, but the “strategic conservatives” wish to corporatize everything and remove the role of philanthropy and grassroots support altogether. That would spell suicide for the longevity field.

The SENS Board stated, “Our respect for Dr. de Grey and his work remains deep and unwavering. His accomplishments are singular; he brought this Foundation — this profound scientific moment, truly — into being. While our separation was necessary, we intend to move forward with SRF in a way that honors his legacy.” Of course, this leaves open the unanswered question of why the Board considered the “separation” to be “necessary” – and why they wish to relegate Dr. de Grey merely to having a “legacy”. (He is very much alive and active, after all!) Most likely, some of them do actually regret this course of action, but their thinking may be along the following lines: “Aubrey de Grey got this movement this far, but from now on he is more of a liability than an asset. We can take it from here.” Well, no, they cannot. In order to have even a slight probability of success, the SENS vision requires support from at least appreciable segments of the general public and from the dedicated core of activists within the life-extension movement. Without them, there is no movement – just stagnation. But there will be a movement wherever Dr. de Grey goes. The SENS Research Foundation Board of Directors would be wise to invite him back.

Thank you to Immortalists Magazine for featuring this article, which will be republished in its blog in November 2021.

Aubrey de Grey Did Not Receive Fair Treatment in the Investigation Commissioned by the Board of Directors of the SENS Research Foundation

Aubrey de Grey Did Not Receive Fair Treatment in the Investigation Commissioned by the Board of Directors of the SENS Research Foundation

Gennady Stolyarov II

I have read the “independent” investigative report that was commissioned by the Board of Directors of the SENS Research Foundation – the same Board that fired Dr. Aubrey de Grey before the investigation was completed and now, it seems, is using this report as ex post justification of its preconceived decision. Here are the insights I can glean from reading this report; not all are original to me, and many have pointed out some of these observations already. However, it is useful to summarize them here to spread understanding of just how flawed this report is.

1. This report underscores the essentially ubiquitous fact that, in corporate America, “he who pays the piper calls the tune”. There is no true possibility of a neutral, independent investigation when the investigator is financially compensated by one of the parties with a preconceived interest in the outcome. Whatever the personal ethics of the investigator, it would remain the case – and this is true for any paid professional contractor – that she would be concerned about where her future revenue stream would be coming from. Releasing a report that challenged or undermined the well-publicized intentions of (and actions already taken by) her clients – the Board of the SENS Research Foundation – would have jeopardized her future opportunities to be retained by the same clients or similar corporate Boards, whose interest is not so much in the objective truth, but rather in ratifying the legitimacy of the Board’s actions after the fact and mitigating adverse publicity.

It was naïve for many of us to give this investigation the benefit of the doubt and hold our peace while it proceeded, with the hope that it might have actually shed light on the situation in an impartial manner. Indeed, the mistake that we supporters of Aubrey de Grey have made is to assume throughout this process that all sides would have the intention of bringing the facts to light and making proportionate conclusions based on the evidence. Instead, the far more typical calculus of “cui bono” and motivated reasoning were clearly in play here.

2. The standard of “preponderance of evidence” utilized in the report is incredibly weak and subjective – essentially amounting to whether, in the opinion of the investigator, a given event was more likely than not to have occurred. This is not proof; it is not beyond reasonable doubt; it is not even clear and convincing evidence. Essentially, all of the assertions in this report are the investigator’s personal opinions that some chain of events was plausible. But the report does not actually bring any fundamentally new factors to light. None of this would hold up in a court of law or any official investigation by a governmental body (and even such an official investigation would not be warranted in any event, because no violation of law was ever made or even alleged).

3. It remains the case, based on what the report was actually able to corroborate, that the only definite actions that Aubrey de Grey was known to have taken were the sending of two ill-advised e-mails nearly a decade ago, which were poorly worded and definitely had a high likelihood of being misunderstood. To be sure, I consider those e-mails to have been a mistake on Aubrey’s part (and he does as well), but they stemmed from his own European cultural context, in which the sentiments expressed would have been considered far more innocuous than they would be in the United States of 2021. To punish a person with a loss of a prominent position and jeopardy to that person’s career, retroactively, for statements that would not have been and were not considered offenses a long time ago when they were made, and which are not at all criminal, civil, or otherwise actionable offenses even today, is a draconian perversion of justice. It implies that not only is anyone vulnerable to incredibly harsh penalties for any mistake or minor lapse in judgment, but even that a comparatively mild statement that would have been dismissed or overlooked in the past could become career-ending retroactively if societal norms change many years later. The fact that “Complainant #1” actively collaborated with Aubrey de Grey for nearly a decade after the ill-advised comments were made suggest that those comments were reinterpreted much more recently to have a motivation that nobody attributed to them in the past.

4. The allegations that Aubrey de Grey “interfered with the investigation” ultimately disregard the possibility that Aubrey could have been genuine in his stated motivation to help rehabilitate the reputation of “Complainant #2” after she made unsupported allegations which could, indeed, have jeopardized her career. The investigator interprets Aubrey’s e-mail to an intermediary as a threat to the career of “Complainant #2”, when Aubrey was much more likely expressing an objective fact – that few people in the longevity industry would be willing to work with someone who makes allegations of predation so lightly. The “Why risk it?” consideration is likely going to lead many in the community to tread extremely lightly around the accusers for the indefinite future. Aubrey himself could have been able to avert that particular outcome if the misunderstandings that prompted the allegations had been resolved.

5. Moreover, if Aubrey de Grey sensed that the investigation was not conducted in an objective or impartial manner, and that the actions of the SENS Research Foundation Board already placed the punishment before any official determination of guilt, then he would have had a clear and highly understandable incentive to attempt to tell his side of the story through channels outside of the investigation. If he had fully complied with the investigator’s admonitions, the outcome would have likely been the same; a determination of his guilt was a foregone conclusion based on the “he who pays the piper” principle. In that situation, Aubrey would have simply quietly acquiesced to his own professional destruction. Perhaps he would have been shown some leniency, perhaps not; the history of show trials demonstrates that compliance and even confessions by the accused seldom improved their outcomes and indeed lent legitimacy to the severe penalties that were imposed.

6. Even this report exonerates Aubrey de Grey from having interfered with the funding of the doctoral research position of “Complainant #2”. This would have been one of the principal allegations explaining the resentment that “Complainant #2” felt against Aubrey de Grey. If the rest of her actions were precipitated by that perception, and the initial perception was mistaken, then it is reasonable to expect that the rest of the narrative motivated by that perception would unravel under closer genuine scrutiny.

7. Moreover, this report, in its own telling, fails to identify any other concrete allegations against Aubrey de Grey beyond the relatively mild allegations which were made by “Complainant #1” and “Complainant #2”. There is no pattern of harassment or abuse, no legions of women who were somehow preyed upon. Indeed, the characterization of predation made by “Complainant #2” against Aubrey de Grey can be seen as clearly libelous even if the investigator’s understanding of the facts were ultimately shown to be correct. The term “predator” should be reserved for the likes of Harvey Weinstein and Jeffrey Epstein, not someone who made a few poorly thought-out attempted compliments from which no other actions ensued – especially considering that many of the years between 2012 and 2021 contained no incidents of any nature documented within the report.

8. The report is sloppily written and has obvious errors in dates. On page 14 of 16 of the report, three e-mails addressed to Aubrey de Grey are mentioned as having dates in July 2019, when the events to which the e-mails refer could clearly only have taken place in July 2021. It seems that the motivation to release a report with these conclusions was so strong that shortcuts were taken in proofreading the report for basic accuracy. While anyone can make typographical errors, a robust internal editing process should have caught them. This also raises the question of what other, more fundamental errors were left undetected in the course of the internal review of drafts of this report.

9. I am left with no option but to conclude that the SENS Research Foundation Board acted in a deliberate and premeditated manner to displace Aubrey de Grey from his Chief Science Officer position, despite Aubrey de Grey being the originator of the SENS program and an indispensable presence to the research efforts that comprise this program. Instead of seeking to facilitate a truly independent investigation that could have brought genuine facts to light and resolved this immense misunderstanding, it is my impression that the SENS Research Foundation Board conceived of the investigation as a tool to validate and ratify the preconceived intention to remove Aubrey from his role. This is why the punishment came before the determination of guilt. This is why the Board failed to utilize the plethora of milder measures that were available to address any concerns of interference with the investigation on Aubrey’s part. I have no doubt that multiple members of the SENS Research Foundation Board are good people and did not intend any harm to Aubrey; I believe, however, that they were tragically misled by those who did have such motives. Perhaps they, too, naïvely believed that the investigation could be truly independent and impartial, rather than motivated by the agenda of whomever got the idea to engage the firm in the first place. Perhaps they thought that an independent investigation that exonerated Aubrey would be trusted more in the court of public opinion than an approach of the organization standing resolutely with one of its own (which is what should have been done, if for no other reason than loyalty to Aubrey and deep respect for his tremendous contributions to aging-research and advocacy endeavors for over two decades). The fact remains, though, that the cynical among the Board members were able to lead the rest along with a plan for the premeditated destruction of Aubrey’s career and reputation. By doing so, they irreparably damaged the standing of the SENS Research Foundation and made it unworthy of the tremendous dedication and trust placed in it by thousands of donors and activists within the longevity community. We always donated and stood by the SENS Research Foundation because of our admiration and support for Aubrey de Grey, not for the people who ousted him. We always understood Aubrey’s efforts to be the impetus behind the SENS Research Foundation; what remains is an empty shell. What could have motivated some on the Board of the SENS Research Foundation to remove Aubrey? The recent immense success of over $28 million collected via the PulseChain Airdrop fundraiser would certainly have been a tempting prize. Those who might have considered Aubrey to be too outspoken, too eccentric, too liable to “damage the respectability” of aging research with establishment “gatekeeper” institutions, would have seen the allegations against Aubrey as a convenient way to sideline him and then take custody of the funds. The tragedy is that now the funds raised through enthusiasm for the cause of longevity are at risk of being directed into more status-quo-acquiescent channels.

10. At this stage I am of the view that Aubrey de Grey should proceed to create a new foundation, where he remains in complete control, and there is good reason to believe that the researchers and new donations will follow his lead. It is unfortunate that the SENS Research Foundation Board has chosen to consign its organization to irrelevance, but we cannot let faux-outrage over some mildly inappropriate comments derail the far more essential mission of saving over 110,000 people who die per day of the diseases of aging. This entire episode also illustrates the folly of setting up organizational boards that are outside the control of the founders and prime movers of the organizations. In such situations, petty, short-sighted, fear-driven, and narrowly conventional motives come necessarily to predominate over the original vision and ambition of the founder(s). After so many stories of founders being displaced by the institutional machinery they have acquiesced to, surely it is time to learn the lesson – both for nonprofit organizations and for-profit startups. An organization succeeds because of the merits and vision of its founder(s); without the founder(s) the organization becomes a mere husk, replicating conventional patterns until it fades into the background with millions of other similar organizations. What we seek, on the other hand, is an organization that will bring humankind into the era of longevity escape velocity. We should all support any efforts by Aubrey de Grey to create such an organization.

U.S. Transhumanist Party Chairman Gennady Stolyarov II Answers Common Interview Questions

U.S. Transhumanist Party Chairman Gennady Stolyarov II Answers Common Interview Questions

Gennady Stolyarov II


Gennady Stolyarov II, Chairman of the U.S. Transhumanist Party and Chief Executive of the Nevada Transhumanist Party, answers questions posed by Francesco Sacco, which are representative of common points of inquiry regarding transhumanism and the Transhumanist Party:

1. What is Transhumanism and what inspired you to follow it?
2. What are the long-term goals of the Transhumanist party?
3. What are your thoughts on death and eternal life through technological enhancements?
4. Do you feel there are any disadvantages to having access to the cure for death? What advantages are there?

Become a member of the U.S. Transhumanist Party for free, no matter where you reside. Fill out our Membership Application Form here.

See Mr. Stolyarov’s presentation, “The U.S. Transhumanist Party: Pursuing a Peaceful Political Revolution for Longevity“.

Beginners’ Explanation of Transhumanism – Presentation by Bobby Ridge and Gennady Stolyarov II

Beginners’ Explanation of Transhumanism – Presentation by Bobby Ridge and Gennady Stolyarov II

Bobby Ridge
Gennady Stolyarov II


Bobby Ridge, Secretary-Treasurer of the U.S. Transhumanist Party, and Gennady Stolyarov II, Chairman of the U.S. Transhumanist Party, provide a broad “big-picture” overview of transhumanism and major ongoing and future developments in emerging technologies that present the potential to revolutionize the human condition and resolve the age-old perils and limitations that have plagued humankind.

This is a beginners’ overview of transhumanism – which means that it is for everyone, including those who are new to transhumanism and the life-extension movement, as well as those who have been involved in it for many years – since, when it comes to dramatically expanding human longevity and potential, we are all beginners at the beginning of what could be our species’ next great era.

Become a member of the U.S. Transhumanist Party for free, no matter where you reside.

See Mr. Stolyarov’s presentation, “The U.S. Transhumanist Party: Pursuing a Peaceful Political Revolution for Longevity“.

In the background of some of the video segments is a painting now owned by Mr. Stolyarov, from “The Singularity is Here” series by artist Leah Montalto.

U.S. Transhumanist Party Discussion Panel on Life Extension – February 18, 2017

U.S. Transhumanist Party Discussion Panel on Life Extension – February 18, 2017

 

The New Renaissance Hat

Listen to and download the audio recording of this panel discussion at http://rationalargumentator.com/USTP_Life_Extension_Panel.mp3 (right-click to download).

For its second expert panel, the U.S. Transhumanist Party invited Bill Andrews, Aubrey de Grey, Ira Pastor, and Ilia Stambler to discuss life extension and the quest to reverse biological aging through science and technology.

This two-hour panel discussion, moderated by Chairman Gennady Stolyarov II, took place on Saturday, February 18, 2017, at 10 a.m. U.S. Pacific Time. In this interactive venue, many opportunities for fresh discourse arose on the possibility of achieving dramatically greater longevity within our lifetimes. The substance of the discussion begins at 4:25 in the recording.

Questions the panelists considered include the following:

(i) How would you characterize the current state of efforts to reverse senescence / lengthen human lifespans?
(ii) How does progress in the areas of research you have delved into compare to your expectations approximately 10 to 15 years ago?
(iii) What are the most significant challenges and obstacles that you perceive to exist in the way of achieving serious reversal of biological aging?
(iv) What key technologies and methods of delivering treatments to patients would need to be developed in order for longevity escape velocity to be affordably achieved society-wide?
(v) What political reforms and societal / attitudinal changes would you advocate to accelerate the arrival of effective treatments to reverse biological aging and lengthen lifespans?
(vi) Are you concerned about any current political trends and how they might affect the progress of research into combating biological aging?
(vii) What can laypersons who are sympathetic to your goals do in order to hasten their realization? How can the effort to defeat aging become as popular and widely supported as efforts to defeat cancer and ALS are today?
(viii) What lessons can the history of anti-aging research offer to those who seek to advocate and help achieve effective scientific breakthroughs in this area in the coming years and decades?

Become a member of the U.S. Transhumanist Party for free. Apply here.

References

Genetic stabilization of transthyretin, cerebrovascular disease, and life expectancy” – Paper by Louise S. Hornstrup, Ruth Frikke-Schmidt, Børge G. Nordestgaard and Anne Tybjærg-Hansen. Arteriosclerosis, Thrombosis, and Vascular Biology. 2013;33:1441-1447, Originally published May 15, 2013.

Recognizing Degenerative Aging as a Treatable Medical Condition: Methodology and Policy” – Paper by Ilia Stambler. Aging and Disease.

***

Panelists

Dr. Bill Andrews is the President and CEO of Sierra Sciences – http://www.sierrasci.com/. As a scientist, athlete, and executive, he continually pushes the envelope and challenges convention. In his 35-year biotech career, he has focused the last 23 years on finding ways to extend the human lifespan and healthspan through telomere maintenance. As one of the principal discoverers of both the RNA and protein components of human telomerase, Dr. Andrews was awarded 2nd place as “National Inventor of the Year” in 1997.

Dr. Aubrey de Grey is the biomedical gerontologist who researched the idea for and founded SENS Research Foundation – http://www.sens.org/. He received his BA in Computer Science and Ph.D. in Biology from the University of Cambridge in 1985 and 2000, respectively. Dr. de Grey is Editor-in-Chief of Rejuvenation Research, is a Fellow of both the Gerontological Society of America and the American Aging Association, and sits on the editorial and scientific advisory boards of numerous journals and organizations.

Ira Pastor has 30 years of experience across multiple sectors of the pharmaceutical industry, including pharmaceutical commercialization, biotech drug development, managed care, distribution, OTC, and retail. He is the CEO of BioQuark, Inc. – http://www.bioquark.com/ – and Executive Chairman of ReAnima Advanced Biosciences – https://reanima.tech/.

Dr. Ilia Stambler is a researcher at Bar Ilan University, Israel. His research focuses on the historical and social implications of aging and life-extension research. He is the author of A History of Life-extensionism in the Twentieth Century – www.longevityhistory.com. He is actively involved in advocacy for aging and longevity research – www.longevityforall.org.

Discussion on Life-Extension Advocacy – G. Stolyarov II Answers Audience Questions

Discussion on Life-Extension Advocacy – G. Stolyarov II Answers Audience Questions

The New Renaissance Hat

G. Stolyarov II

******************************

Gennady Stolyarov II, Chairman of the U.S. Transhumanist Party, answers audience questions regarding life-extension advocacy and possibilities for broadening the reach of transhumanist and life-extensionist ideas.

While we were unable to get into contact with our intended guest, Chris Monteiro, we were nonetheless able to have a productive, wide-ranging discussion that addressed many areas of emerging technologies, as well as trends in societal attitudes towards them and related issues of cosmopolitanism, ideology, and the need for a new comprehensive philosophical paradigm of transmodernism or hypermodernism that would build off of the legacy of the 18th-century Age of Enlightenment.

Become a member of the U.S. Transhumanist Party for free. Apply here.

UNITY Biotechnology Raises $116M for Senescent Cell Clearance Development – Article by Reason

UNITY Biotechnology Raises $116M for Senescent Cell Clearance Development – Article by Reason

The New Renaissance HatReason
******************************

The whispers of late have had it that UNITY Biotechnology was out raising a large round of venture funding, and their latest press release shows that this was indeed the case. The company, as you might recall, is arguably the more mainstream of the current batch of startups targeting the clearance of senescent cells as a rejuvenation therapy. The others include Oisin Biotechnologies, SIWA Therapeutics, and Everon Biosciences, all with different technical approaches to the challenge. UNITY Biotechnology is characterized by a set of high profile relationships with noted laboratories, venture groups, and big names in the field, and, based on the deals they are doing, appear to be focused on building a fairly standard drug development pipeline: repurposing of apoptosis-inducing drug candidates from the cancer research community to clear senescent cells, something that is being demonstrated with various drug classes by a range of research groups of late. Senescent cells are primed to apoptosis, so a nudge in that direction provided to all cells in the body will have little to no effect on normal cells, but tip a fair proportion of senescent cells into self-destruction. Thus the UNITY Biotechnology principals might be said to be following the standard playbook to build the profile of a hot new drug company chasing a hot new opportunity, and clearly they are doing it fairly well so far.

UNITY Biotechnology Announces $116 Million Series B Financing

Quote:

UNITY Biotechnology, Inc. (“UNITY”), a privately held biotechnology company creating therapeutics that prevent, halt, or reverse numerous diseases of aging, today announced the closing of a $116 million Series B financing. The UNITY Series B financing ranks among the largest private financings in biotech history and features new investments from longtime life science investors ARCH Venture Partners, Baillie Gifford, Fidelity Management and Research Company, Partner Fund Management, and Venrock. Other investors include Bezos Expeditions (the investment vehicle of Jeff Bezos) and existing investors WuXi PharmaTech and Mayo Clinic Ventures. Proceeds from this financing will be used to expand ongoing research programs in cellular senescence and advance the first preclinical programs into human trials.

The financing announcement follows the publication of research that further demonstrates the central role of senescent cells in disease. The paper, written by UNITY co-founders Judith Campisi and Jan van Deursen and published today, describes the central role of senescent cells in atherosclerotic disease and demonstrates that the selective elimination of senescent cells holds the promise of treating atherosclerosis in humans. In animal models of both early and late disease, the authors show that selective elimination of senescent cells inhibits the growth of atherosclerotic plaque, reduces inflammation, and alters the structural characteristics of plaque such that higher-risk “unstable” lesions take on the structural features of lower-risk “stable” lesions. “This newly published work adds to the growing body of evidence supporting the role of cellular senescence in aging and demonstrates that the selective elimination of senescent cells is a promising therapeutic paradigm to treat diseases of aging and extend healthspan. We believe that we have line of sight to slow, halt, or even reverse numerous diseases of aging, and we look forward to starting clinical trials with our first drug candidates in the near future.”

So this, I think, bodes very well for the next few years of rejuvenation research. It indicates that at least some of the biotechnology venture community understands the likely true size of the market for rejuvenation therapies, meaning every human being much over the age of 30. It also demonstrates that there is a lot of for-profit money out there for people with credible paths to therapies to treat the causes of aging. It remains frustrating, of course, that it is very challenging to raise sufficient non-profit funds to push existing research in progress to the point at which companies can launch. This is a problem throughout the medical research and development community, but it is especially pronrounced when it comes to aging. The SENS view of damage repair, which has long incorporated senescent cell clearance, is an even tinier and harder sell within the aging research portfolio – but one has to hope that funding events like this will go some way to turn that around.

From the perspective of being an investor in Oisin Biotechnologies, I have to say that this large and very visible flag planted out there by the UNITY team is very welcome. The Oisin team should be able to write their own ticket for their next round of fundraising, given that the gene therapy technology they are working on has every appearance of being a superior option in comparison to the use of apoptosis-inducing drugs: more powerful, more configurable, and more adaptable. When you are competing in a new marketplace, there is no such thing as too much validation. The existence of well-regarded, well-funded competitors is just about the best sort of validation possible. Well-funded competitors who put out peer-reviewed studies on a regular basis to show that the high-level approach you and they are both taking works really well is just icing on the cake. Everyone should have it so easy. So let the games commence! Competition always drives faster progress. Whether or not I had skin in this game, it would still be exciting news. The development of rejuvenation therapies is a game in which we all win together, when new treatments come to the clinic, or we all lose together, because that doesn’t happen fast enough. We can and should all of us be cheering on all of the competitors in this race. The quality and availability of the outcome is all that really matters in the long term. Money comes and goes, but life and health is something to be taken much more seriously.

Now with all of that said, one interesting item to ponder in connection to this round of funding for UNITY is the degree to which it reflects the prospects for cancer therapies rather than the prospects for rejuvenation in the eyes of the funding organizations. In other words, am I being overly optimistic in reading this as a greater understanding of the potential for rejuvenation research in the eyes of the venture community? It might be the case that the portions of the venture community involved here understand the market for working cancer drugs pretty well, and consider that worth investing in, with the possibility of human rejuvenation as an added bonus, but not one that is valued appropriately in their minds. Consider that UNITY Biotechnology has partnered with a noted cancer therapeutics company, and that the use of drugs to inducing apoptosis is a fairly well established approach to building cancer treatments. That is in fact why there even exists a range of apoptosis-inducing drugs and drug candidates for those interested in building senescent cell clearance therapies to pick through. Further, the presence of large numbers of senescent cells does in fact drive cancer, and modulating their effects (or removing them) to temper cancer progress is a topic under exploration in the cancer research community. So a wager on a new vision, or a wager on the present market? It is something to think about.

Reason is the founder of The Longevity Meme (now Fight Aging!). He saw the need for The Longevity Meme in late 2000, after spending a number of years searching for the most useful contribution he could make to the future of healthy life extension. When not advancing the Longevity Meme or Fight Aging!, Reason works as a technologist in a variety of industries.
***
This work is reproduced here in accord with a Creative Commons Attribution license. It was originally published on FightAging.org.
An Example of the Glaring Lack of Ambition in Aging Research – Post by Reason

An Example of the Glaring Lack of Ambition in Aging Research – Post by Reason

The New Renaissance HatReason
******************************

The mainstream of aging research, at least in public, is characterized by a profound lack of ambition when it comes to treating aging as a medical condition. Researchers talk about slightly altering the trajectory of aging as though that is the absolute most that is possible, the summit of the mountain, and are in many cases ambivalent when it comes to advocating for even that minimal goal. It is this state of affairs that drove Aubrey de Grey and others into taking up advocacy and research, given that there are clear paths ahead to rejuvenation, not just a slight slowing of aging, but halting and reversing the causes of aging. Arguably embracing rejuvenation research programs would in addition cost less and take a much shorter span of time to produce results, since these programs are far more comprehensively mapped out than are efforts to produce drugs to alter the complex operations of metabolism so as to slightly slow the pace at which aging progresses. It is most frustrating to live in a world in which this possibility exists, yet is still a minority concern in the research community. This article is an example of the problem, in which an eminent researcher in the field takes a look at a few recently published books on aging research, and along the way reveals much about his own views on aging as an aspect of the human condition that needs little in the way of a solution. It is a terrible thing that people of this ilk are running the institutes and the funding bodies: this is a field crying out for disruption and revolution in the name of faster progress towards an end to aging.

How can we overcome our niggling suspicion that there is something dubious, if not outright wrong, about wanting to live longer, healthier lives? And how might we pursue longer lives without at the same time falling prey to quasiscientific hype announcing imminent breakthroughs? In order to understand why aging is changing, and what this means for our futures, we need to learn more about the aging process itself. As a biologist who specializes in aging, I have spent more than four decades on a quest to do exactly this. Not only have I asked why aging should occur at all (my answer is encapsulated in a concept called disposability theory), but I have also sought to understand the fastest-growing segment of the population – those aged 85 and above. The challenges inherent in understanding and tackling the many dimensions of aging are reflected in a clutch of new books on the topic. Are these books worth reading? Yes and no. They take on questions like: Can we expect increases in human longevity to continue? Can we speed them up? And, on the personal level, what can we do to make our own lives longer and healthier? If nothing else, these books and their varied approaches reveal how little we actually know.

To find out more about factors that can influence our individual health trajectories across ever-lengthening lives, my colleagues and I began, in 2006, the remarkable adventure of the still ongoing Newcastle 85+ Study, an extremely detailed investigation of the complex medical, biological, and social factors that can affect a person’s journey into the outer reaches of longevity. For each individual, we determined whether they had any of 18 age-related conditions (e.g., arthritis, heart disease, and so on). Sadly, not one of our 85-year-olds was free of such illnesses. Indeed, three quarters of them had four or more diseases simultaneously. Yet, when asked to self-rate their health, an astonishing 78 percent – nearly four out of five – responded “good,” “very good,” or “excellent.” This was not what we had expected. The fact that these individuals had so many age-related illnesses fit, of course, with the popular perception of the very old as sadly compromised. But the corollary to this perception – that in advanced old age life becomes a burden, both to the individuals themselves and to others – was completely overturned. Here were hundreds of old people, of all social classes and backgrounds, enjoying life to the fullest, and apparently not oppressed by their many ailments.

As for my stake in the enterprise, I began investigating aging when I was in my early 20s – well before I had any sense of my own body aging. Quite simply, I was curious. What is this mysterious process, and why does it occur? Everything else in biology seems to be about making things work as well as they can, so how is it that aging destroys us? Now that I am growing older myself, my research helps me understand my own body and reinforces the drive to live healthily – to eat lightly and take exercise – though not at the cost of eliminating life’s pleasures. For all that I have learned about aging, my curiosity remains unabated. Indeed, it has grown stronger, partly because as science discovers more about the process, it reveals that there is ever more to learn, ever greater complexity to unravel, and partly because I am now my own subject: through new physical and psychological experiences in myself, I learn more about what older age is really like. I know all too well that the next phase of my life will bring unwelcome changes, and of course it must end badly. But the participants of the Newcastle 85+ Study have shown me that the journey will not be without interest.

Link: https://lareviewofbooks.org/article/want-live-longer-complicated-relationship-longevity/

Reason is the founder of The Longevity Meme (now Fight Aging!). He saw the need for The Longevity Meme in late 2000, after spending a number of years searching for the most useful contribution he could make to the future of healthy life extension. When not advancing the Longevity Meme or Fight Aging!, Reason works as a technologist in a variety of industries.
***
This work is reproduced here in accord with a Creative Commons Attribution license. It was originally published on FightAging.org.
An Interview with Kelsey Moody of Ichor Therapeutics, Bringing a SENS Therapy for Macular Degeneration to the Clinic – Article by Reason

An Interview with Kelsey Moody of Ichor Therapeutics, Bringing a SENS Therapy for Macular Degeneration to the Clinic – Article by Reason

The New Renaissance HatReason
******************************

As I mentioned last week, earlier this year Fight Aging! invested a modest amount in the Ichor Therapeutics initiative to develop a treatment for macular degeneration, joining a number of other amateur and professional investors in helping to get this venture started. The approach taken here is based on the results of research carried out at the Methuselah Foundation and SENS Research Foundation over much of the past decade, funded by philanthropists and the support of our community of longevity science enthusiasts. This is how we succeed in building the future: medical science in the laboratory leads to medical development in startup companies, each new stage bringing treatments capable of repairing specific forms of age-related molecular damage that much closer to the clinic.

Ichor Therapeutics is one of a growing number of success stories to emerge from the SENS rejuvenation research community. Young scientists, advocates, and donors involved in earlier projects – years ago now – have gone on to build their own ventures, while retaining an interest in stepping up to do something meaningful to help bring an end to aging. Back in 2010, Kelsey Moody worked on the LysoSENS project to find ways to break down damaging metabolic waste in old tissues; fast-forward six years, and he is the now the CEO of a successful small biotechnology company with a great team, taking that very same technology and putting it to good use. I recently had the chance to ask Kelsey a few questions about the future of SENS rejuvenation research, as well as how the Ichor scientists intend to construct a new class of therapy for macular degeneration, one based on removing one of the root causes of the condition.

Quote:

Who are the people behind Ichor Therapeutics? How did you meet and decide that this was the thing to do? Why macular degeneration as a target?

People have always been the focus of Ichor. Since day one we have worked to create a positive environment that cultivates a product-oriented research focus and emphasizes autonomy and personal accountability for work. As a result, ambitious self-starters tend to find their way to Ichor and remain here. However, we recognized early on that just filling a lab with a bunch of blue-eyed bushy tailed young up-and-comers is not sufficient to develop a robust, mature, translational pipeline. We have augmented our team with a number of critical staff members who are seasoned pharma operators, including our Quality Assurance Director and General Counsel.

Age-related macular degeneration (AMD) was chosen as a target because we believe it is the closest SENS therapy to the clinic. While we obviously have an interest in providing cures for the patients suffering from AMD and are attracted to the large market opportunities such a treatment could bring, our broader interest is in validating the entire SENS paradigm. We believe that Aubrey de Grey continues to receive excessive criticism because nothing spun out of SENS has ever made it into a legitimate pre-clinical pipeline, much less to the bedside. However, this does not mean he is wrong. Our goal is to be the first group to bring a SENS inspired therapy into the clinic and in doing so, silence critics and generate new energy and capital for this cause.

I understand there’s a lengthy origin story for the approach you are taking to treat AMD; it’d be great to hear some of it.

Our approach to treating AMD is based on the hypothesis that cellular junk that accumulates over the lifespan significantly contributes to the onset and progression of AMD. Our goal is to periodically reduce the burden of the junk so it never accumulates to levels sufficient to induce pathology. The strategy to accomplish this calls for the identification of enzymes that can break down the junk in a physiological setting, and the engineering of these enzymes such that they can break down the target in the correct organelle of the correct cell without appreciable collateral damage to healthy cells or tissue.

Methuselah Foundation and SENS Research Foundation did excellent work in establishing this program nearly a decade ago. They successfully identified a number of candidate enzymes that could break down the molecular junk, but reported that the targeting systems evaluated failed to deliver these enzymes to the appropriate organelles and cells. My group reevaluated these findings, and discovered that these findings were flawed. The delivery failure could be entirely attributed to a subtle, yet highly significant difference between how the target cells behave outside of the body as compared to inside the body. It turned out that the approach was in fact valid, it was the cell based assay that had been used that was flawed. This discovery was striking enough that SENS Research Foundation provided Ichor with funding and a material and technology transfer agreement to reassess the technology, and over $700,000 in directed program investments and grants have been received in the last year or two.

You recently completed a round of funding for the AMD work; what is the plan for the next year or so?

The new funds will allow us to develop a portfolio of enzyme therapy candidates to treat AMD. We will obtain critical data necessary to secure follow-on investment including in vitro studies (cell culture studies to confirm mechanism of action and cytotoxicity) and pivotal proof-of-concept in vivo studies, such as toxicity, PK/PD (how long the enzyme stays in the body and where), and efficacy. We will also be restructuring the company (reincorporating an IP holding company in Delaware, ensuring all contracts are up to date and audited) and ensuring our IP position is on solid footing (licensing in several related patents from existing collaborators, and filing several provisional patents from our intramural work). Collectively, we believe these efforts will position us to obtain series A for investigational new drug (IND) enabling pre-clinical studies.

You’ve been involved in the rejuvenation research community for quite some time now. What is your take on the bigger picture of SENS and the goal of ending aging?

This is a loaded question. What I can say is that the medical establishment has made great progress in the treatment of infectious disease through the development of antibiotics, vaccines, and hygiene programs. However, similar progress has not been realized for the diseases of old age, despite exorbitant expenditures. I have chosen to work in this space because I think a different approach is necessary, and it is here that I believe my companies and I can be the most impactful. I think SENS provides a good framework within which to ask and answer questions.

What do you see as the best approach to getting nascent SENS technologies like this one out of the laboratory and into the clinic?

We need more people who fully understand, in a highly detailed way, what a real translational path looks like. To take on projects like this, being a good scientist is not enough. We need people who can speak business, science, medicine, and legal, and apply these diverse disciplines to a well articulated, focused product or problem. There is no shortage of people who partially understand some of these, but the details are not somewhat important – they are all that matter for success in this space.

Another area is for investors. Some of the projects that come across my desk for review are truly abysmal, yet I have seen projects that are clearly elaborate hoaxes or outright scams (to anyone who has stepped foot in a laboratory) get funded to the tune of hundreds of thousands of dollars or more. While it is perfectly reasonable for high net worth individuals to gamble on moon shots in the anti-aging space (and I am ever grateful for the investors who have taken such a gamble on us) even aggressive development strategies should have some basis in reality. This is especially true as more and more high tech and internet investors move into the space.

If this works stupendously well, what comes next for Ichor Therapeutics?

I really want to get back into stem-cell research, but I basically need a blank check and a strong knowledge of the regulatory path to clinic before I feel comfortable moving into the space. A successful AMD exit would accomplish both of these goals, and position us to pivot to cell-based therapies.

Reason is the founder of The Longevity Meme (now Fight Aging!). He saw the need for The Longevity Meme in late 2000, after spending a number of years searching for the most useful contribution he could make to the future of healthy life extension. When not advancing the Longevity Meme or Fight Aging!, Reason works as a technologist in a variety of industries.
***
This work is reproduced here in accord with a Creative Commons Attribution license. It was originally published on FightAging.org.
Aubrey de Grey at the Launching Longevity Panel, and Announcing Acceptance of the First Paper to be Published on MitoSENS Research – Article by Reason

Aubrey de Grey at the Launching Longevity Panel, and Announcing Acceptance of the First Paper to be Published on MitoSENS Research – Article by Reason

The New Renaissance HatReason
******************************

Today I’ll direct your attention to a couple of videos, thematically linked by the presence of Aubrey de Grey, cofounder of the SENS Research Foundation and tireless advocate for progress towards working rejuvenation therapies. For the first of the videos, de Grey recently took part in a panel discussion involving representatives of the biotechnology industry, the research establishment, and venture capital community, with the topic being the coming development of a new industry that will develop therapies to extend healthy life and turn back aging. That industry has barely started to form its earliest and smallest stage today, as the first lines of rejuvenation research reach the point of commercial viability. There are a few startups and a lot of deep pockets yet to be convinced that this is going somewhere – though the commentary in the panel is encouraged, considering those involved.

The recent Rejuvenation Biotechnology 2016 conference hosted by the SENS Research Foundation was more along the same lines, focused on creating a foundation for the near future industry that will build and provide rejuvenation therapies. The purpose of the conference series is to help smooth the way for these treatments to move rapidly from the laboratory to the clinic, to build the necessary relationships, manage expectations, and pull in the additional support needed to make best possible progress. The conference was livestreamed over the past couple of days, and at one point Aubrey de Grey announced the just-then-and-there acceptance of the first scientific publication for the MitoSENS team at the SENS Research Foundation. They are presently in the lead, at the cutting edge, among the few groups working on the project of copying mitochondrial genes into the cell nucleus to protect them from the damage of aging. Ultimately, copying all thirteen genes should completely remove the contribution of mitochondrial damage to degenerative aging, as mitochondria will no longer become dysfunctional as their local DNA is damaged. They will get the proteins they need from the cell nucleus instead. It is a worthy project, and it is always welcome to see progress on this front.

Launching Longevity: Funding the Fountain of Youth

 

Can technology make human longevity a reality? As the pace of discovery accelerates, scientists and entrepreneurs are closing in on the Fountain of Youth. Disrupting the aging process by hacking the code of life, promises better health and longer maximum lifespans. With many layers of complexity from science to ethics, there are still skeptics placing odds against human longevity. Venture capitalists are betting on success; putting big money on the table to fund longevity startups. Google/Alphabet and drugmaker AbbVie have invested $1.5 billion on Calico, while Human Longevity Inc. recently raised $220 million from their Series B funding round. Complementing traditional venture investment, VCs like Peter Thiel and Joon Yun have established foundations and prizes to accelerate the end of aging. Why are VCs suddenly investing heavily in longevity startups? Will extended lifespan be a privilege of the wealthy or will the benefits be accessible to all? How long before these well-funded startups bring viable products to market?

 

Aubrey de Grey Announces Progress in MitoSENS

 

Ok everybody, before I introduce the next session I just wanted to make a very small, brief, but very welcome announcement. Literally half an hour ago we received some extremely good scientific news. Those of you who have been following SENS research since before the SENS Research Foundation itself even existed will know that, about a decade ago, the very first project, the very first research program that we were able to initiate – with the help of, especially, the initial donation of Peter Thiel – was to make mitochondrial mutations harmless by essentially putting backup copies of the mitochondrial DNA into the nuclear genome, modified in such way of course that the encoded proteins would be colocated back into the mitochondria to do their job. This is an idea that was first put forward more than 30 years ago, but it is an idea that despite quite a bit of initial effort, nobody was able to make work. When I first came across this concept, in fact I’d thought of it myself, it’s a pretty obvious idea really, I came to the conclusion that a lot of the despair and despondency and pessimism about this approach was premature, and that it was worth having another go, and so that was the very first project we decided to fund.

Suffice to say that it has not been quite as easy as I was hoping to make progress in that space, but progress has now been made, step by step, over the past several years, with the help especially of the absolutely amazing team we have at the research center, who work on this, headed by Matthew O’Connor. Amutha Boominathan is the number two on the team, and is absolutely indispensable, I’ve no idea where we’d be without her. So, what’s happened half an hour ago is that for the very first time in the entire history of this project, we have got far enough to have a paper accepted in a very nice journal, Nucleic Acids Research, which reports on our progress in this area. The headline result in this paper is that we are the first team ever to get two of the proteins encoded by genes in the mitochondrial DNA simultaneously functioning in the same cell line, and of course – two is equivalent to infinity for mathematicians, you know that, right? – this is extremely heartening news, and I just wanted to let you all know, thank you.

Reason is the founder of The Longevity Meme (now Fight Aging!). He saw the need for The Longevity Meme in late 2000, after spending a number of years searching for the most useful contribution he could make to the future of healthy life extension. When not advancing the Longevity Meme or Fight Aging!, Reason works as a technologist in a variety of industries.
This work is reproduced here in accord with a Creative Commons Attribution license. It was originally published on FightAging.org.